Quick Links

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps
The Expert Perspectives in PARP Inhibition: Evolving Management Strategies in Ovarian Cancer CME-certified satellite symposium was held adjunct to the 47th Society of Gynecologic Oncology (SGO) Annual Meeting on March 19, 2016, in San Diego, California. This symposium brought together top experts in the field of ovarian cancer to review the biologic rationale and available clinical data regarding the efficacy and safety of PARP inhibitors in advanced ovarian cancer, and to discuss both investigational directions and practical strategies for integrating these agents into clinical practice.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Clovis Oncology; Foundation Medicine, Inc; and Myriad Genetics, Inc.

Community Practice Connections™: Expert Perspectives in PARP Inhibition: Evolving Management Strategies in Ovarian Cancer

Release Date: June 24, 2016
Expiration Date: June 24, 2017
Media: Internet - based

Activity Overview

This activity focuses on management strategies in ovarian cancer and features a series of short video interviews with leading experts in the treatment of ovarian cancer. The content and interviews are based on presentations given at Expert Perspectives in PARP Inhibition: Evolving Management Strategies in Ovarian Cancer, a CME-certified, ancillary satellite symposium held at the Annual Meeting on Women’s Cancer®.

CME Activity Table of Contents

  • Mechanism of Action of PARP Inhibitors and Drug Resistance
  • Current Landscape – PARP as a Single Agent
  • Combination Therapy with PARP Inhibitors
  • Where Have We Been with PARP in Ovarian Cancer and Where Are We Going?

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists, gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists who treat patients with ovarian cancer. Obstetrician/gynecologists, nurses, physician assistants, fellows, residents, and other healthcare professionals interested in the treatment of ovarian cancer may also participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Describe the emerging role of PARP inhibitors as single-agent therapies within the current treatment paradigm for recurrent ovarian cancer
  • Discuss the role of genetic testing and the expansion of PARP inhibitors into treatment for patients outside of the BRCA-mutant population
  • Discuss the mechanisms of action of PARP inhibitors
  • Increase awareness of current ongoing clinical trials that are testing PARP inhibitors, including novel combination approaches

Faculty, Staff, and Planners' Disclosures


Michael J. Birrer, MD, PhD
Professor of Medicine, Harvard Medical School
Director, Gillette Center for Gynecologic Oncology
Massachusetts General Hospital
Boston, MA
Disclosure: No relevant financial relationships with commercial interests.

Maurie Markman, MD
President, CTCA Medicine and Science
Cancer Treatment Centers of America
Philadelphia, PA
Disclosure: Consultant: Amgen, Celgene, CritiTech; Speaker's Bureau: Genentech, AstraZeneca.


Joyce Liu, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Physician, Dana-Farber Cancer Institute
Boston, MA
Disclosure: Consultant: AstraZeneca; Investigational/Off-Label Use of Drugs or Device: Olaparib, Veliparib, Niraparib, Rucaparib, Talazoparib.

James Tate Thigpen, MD
Professor of Medicine
Director, Division of Hematology and Oncology
The University of Mississippi Medical Center
Jackson, MS
Disclosure: Speaker's Bureau: Amgen, Boehringer Ingelheim, Genentech, Janssen Biotech, AstraZeneca, Lilly.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By